COMPANY

Corporate History

April 2002 Acugen Neuropeutics Inc. was established in Seattle, Washington USA, under the laws of State of Washington to develop methods of the treatment for degenerative eye diseases and pharmaceutical compound screening system
March 2003 Acugen Neuropeutics Inc. renamed as Acucela Inc.
October 2005 Initiated Visual Cycle Modulation (VCM) development
March 2006 Relocation of Acucela headquarters to Bothell, Washington
April 2006 Initiated development for emixustat, the lead VCM-based product candidate for the treatment of retinal diseases
August 2006 Opened the Tokyo Office in Shinagawa ward in Tokyo
July 2007 Initiated pre-clinical trials for emixustat
April 2008 The Investigational New Drug (IND) for emixustat was filed with the US Food and Drug Administration (FDA)
September 2008 Announced co-development and commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for emixustat
March 2010 Announced FDA Fast Track designation for emixustat
September 2010 Announced relocation of headquarters to Seattle, Washington
September 2013 Tokyo Office relocated to Shibuya ward in Tokyo
February 2014 Initial Public Offering on Tokyo Stock Exchange Mothers Board
March 2014 Announced completion of enrollment in Phase 2b/3 clinical trial of emixustat
May 2015 Announced publication of pre-clinical data of emixustat
June 2015 Announced publication of results from Phase 2a clinical trial of emixustat
December 2015 Incorporated a subsidiary, Acucela Japan KK (current Kubota Pharmaceutical Holdings Co., Ltd.) in Japan
May 2016 Announced top-line results from Phase 2b/3 clinical trial of emixustat
June 2016 Announced the termination of co-development and promotion agreement with Otsuka Pharmaceutical Co., Ltd.
December 2016 Completed the triangle merger and the redomicile transaction; Acucela Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd.
December 2016 Kubota Pharmaceutical Holdings Co., Ltd. listed on the Tokyo Stock Exchange Mothers Board
June 2017 Tokyo Office relocated to Chiyoda ward in Tokyo